AstraZeneca’s Farxiga data shows widespread undiagnosed chronic kidney disease
INSIDE-CKD study involves patients from across France, Germany, Italy, the US and Japan
Read More
Tag: Farxiga
AZ’s Farxiga scores US approval in chronic kidney disease
SGLT2 inhibitor approved for high-risk patients with and without type 2 diabetes
Read More
Farxiga fails to achieve statistical significance in COVID-19 trial
Diabetes drug was unable to prevent all-cause mortality in Phase III study
Read More
US priority review for Forxiga in chronic kidney disease
AZ is aiming for approval in adults with and without type 2 diabetes
Read More
AZ’ Farxiga hits all goals in chronic kidney disease trial
The drug significantly reduced the worsening of renal function or risk of death in patients with chronic kidney disease with and without type II diabetes
Read More
AZ’ Farxiga fast-tracked for heart failure following MI
The move is based on the first indication-seeking registry-based randomised controlled trial
Read More
US OK’s AZ’ Farxiga for heart failure with reduced ejection fraction
Farxiga is the first sodium glucose co-transporter 2 inhibitor cleared by the FDA to treat heart failure with reduced ejection fraction
Read More
AZ, Saint Luke’s begin testing Farxiga for COVID-19
DARE-19 will determine whether Farxiga can hold back disease progression and reduce the risk of clinical complications and death
Read More
AZ scores Priority Review with Farxiga
The US FDA accepted a supplemental New Drug Application for the treatment.
Read More
AZ’ Farxiga hit with complete response letter
AstraZeneca has said that it will work closely with the FDA to discuss the next steps.
Read More
AZ’ Farxiga shows 47% reduction in kidney function decline
The SGLT2 inhibitor was evaluated in 17,160 patients with type II diabetes.
Read More
AZ’ Farxiga shows CV benefit in diabetes patients
New analysis of trial data highlight cardiovascular benefits of AstraZeneca’s diabetes drug Farxiga.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
